Viridian Therapeutics, Inc. (VRDN)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
18.99 USD
-0.75
(-3.799%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:29 a.m. EDT
The recent FDA approval of Lumvoa for Thyroid Eye Disease is a monumental milestone that validates the company's core technology, yet the stock remains deeply distressed. The market is punishing the company for its historical inability to translate scientific success into commercial reality, highlighted by a catastrophic 85% drop over the last nine years and a history of missed targets. Fundamentally, the business is broken: it burns cash aggressively with negative free cash flow, operates at massive losses, and trades at a premium valuation despite having no earnings. The balance sheet, while currently liquid, cannot sustain indefinite burn without a successful commercial launch. The options market confirms this pessimism, with traders stacking put options to hedge against further failure. While the 'Strong Buy' analyst consensus reflects the potential of the new drug, the current price action and structural decline suggest the market views this as a high-risk turnaround play rather than a solid investment. Until the company demonstrates consistent profitability or a proven path to commercial scale, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.180400 |
| AutoARIMA | 0.206097 |
| AutoETS | 0.206097 |
| AutoTheta | 0.206166 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 1.60 |
| Ljung-Box p | 0.002 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.388 |
| Revenue per Share | 0.788 |
| Market Cap | 2,097,021,568 |
| Forward P/E | -7.21 |
| Beta | 0.90 |
| Previous Name | Miragen Therapeutics |
| Website | https://www.viridiantherapeutics.com |
As of July 11, 2026, 5:29 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (especially the $16 strike expiring in October) compared to negligible call volume. While there is some volume at the $33 strike, the overwhelming capital allocation is defensive, suggesting a fear of further decline rather than a bullish bet on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.16789663 |
| Address1 | 221 Crescent Street |
| Address2 | Suite 103A |
| All Time High | 2,247.75 |
| All Time Low | 4.665 |
| Ask | 24.24 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,783,370 |
| Average Daily Volume3 Month | 2,543,426 |
| Average Volume | 2,543,426 |
| Average Volume10Days | 2,783,370 |
| Beta | 0.895 |
| Bid | 14.04 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 4.919 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.99 |
| Current Ratio | 15.148 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 19.66 |
| Day Low | 18.9 |
| Debt To Equity | 8.388 |
| Display Name | Viridian Therapeutics |
| Dividend Date | 1,605,225,600 |
| Earnings Call Timestamp End | 1,715,169,600 |
| Earnings Call Timestamp Start | 1,715,169,600 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -385,233,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.584 |
| Enterprise To Revenue | 19.468 |
| Enterprise Value | 1,380,614,272 |
| Eps Current Year | -3.79937 |
| Eps Forward | -2.63239 |
| Eps Trailing Twelve Months | -3.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 272 4601 |
| Fifty Day Average | 17.1684 |
| Fifty Day Average Change | 1.8216 |
| Fifty Day Average Change Percent | 0.10610191 |
| Fifty Two Week Change Percent | 16.789663 |
| Fifty Two Week High | 34.29 |
| Fifty Two Week High Change | -15.300001 |
| Fifty Two Week High Change Percent | -0.44619426 |
| Fifty Two Week Low | 13.18 |
| Fifty Two Week Low Change | 5.8099995 |
| Fifty Two Week Low Change Percent | 0.44081938 |
| Fifty Two Week Range | 13.18 - 34.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,098,200,000 |
| Float Shares | 97,762,268 |
| Forward Eps | -2.63239 |
| Forward P E | -7.2139764 |
| Free Cashflow | -182,550,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 252 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -268,720,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00137 |
| Held Percent Institutions | 1.1142299 |
| Implied Shares Outstanding | 110,427,682 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,605,225,600 |
| Last Split Factor | 1:15 |
| Long Business Summary | Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts. |
| Long Name | Viridian Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,097,021,568 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_45015663 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -303,267,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,095,917,404 |
| Number Of Analyst Opinions | 16 |
| Open | 19.5 |
| Operating Cashflow | -303,392,000 |
| Operating Margins | -823.8936 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 272 4600 |
| Pre Market Change | -0.09000015 |
| Pre Market Change Percent | -0.47393447 |
| Pre Market Price | 18.9 |
| Pre Market Time | 1,784,029,397 |
| Prev Name | Miragen Therapeutics |
| Previous Close | 19.74 |
| Price Eps Current Year | -4.998197 |
| Price Hint | 2 |
| Price To Book | 3.8605406 |
| Price To Sales Trailing12 Months | 29.569666 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.712 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.17647 |
| Region | US |
| Regular Market Change | -0.75 |
| Regular Market Change Percent | -3.79939 |
| Regular Market Day High | 19.66 |
| Regular Market Day Low | 18.9 |
| Regular Market Day Range | 18.9 - 19.66 |
| Regular Market Open | 19.5 |
| Regular Market Previous Close | 19.74 |
| Regular Market Price | 18.99 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,188,473 |
| Return On Assets | -0.3325 |
| Return On Equity | -0.58137 |
| Revenue Growth | 0.958 |
| Revenue Per Share | 0.788 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 110,427,682 |
| Shares Percent Shares Out | 0.1571 |
| Shares Short | 17,342,672 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,597,487 |
| Short Name | Viridian Therapeutics, Inc. |
| Short Percent Of Float | 0.16290002 |
| Short Ratio | 7.56 |
| Source Interval | 15 |
| State | MA |
| Symbol | VRDN |
| Target High Price | 50.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 36.125 |
| Target Median Price | 35.0 |
| Total Cash | 762,180,992 |
| Total Cash Per Share | 7.394 |
| Total Debt | 53,350,000 |
| Total Revenue | 70,918,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.1202 |
| Two Hundred Day Average Change | -5.1301994 |
| Two Hundred Day Average Change Percent | -0.21269308 |
| Type Disp | Equity |
| Volume | 1,188,473 |
| Website | https://www.viridiantherapeutics.com |
| Zip | 2,453 |